In a move signaling renewed aggression in pharmaceutical M&A, Germany's Merck KGaA stands poised to finalize its largest therapeutic acquisition in a decade with the $3.5 billion purchase of...
As global trade tensions escalate under the Trump administration's tariff policies, Roche AG has emerged as a pivotal player in reshaping pharmaceutical manufacturing strategies. The Basel-based...
In a strategic move that reshapes North America's healthcare logistics landscape, United Parcel Service (NYSE: UPS) announced today its definitive agreement to acquire Toronto-based Andlauer...
In a move signaling private equity's growing appetite for life sciences infrastructure, KKR & Co. launched a $1.2 billion cash offer for Swedish separations technology leader Biotage AB on April 22,...
The pharmaceutical and biotechnology sectors face unprecedented disruption as President Trump's proposed 10-25% tariffs on imported drugs and medical devices threaten to upend global supply chains,...
Private equity heavyweight Bain Capital is finalizing a $2.6 billion acquisition of healthcare technology leader HealthEdge Software from Blackstone Group, according to multiple sources familiar...
Strategic Acquisition: Eli Lilly's potential acquisition of Scorpion Therapeutics signals a strategic move to bolster its oncology pipeline and enhance innovation capabilities. Biotech Market...
Strategic Rationale: Biogen's bid to acquire Sage Therapeutics' remaining stake aligns with its long-term strategy to expand neuroscience capabilities and strengthen its psychiatric and neurological...
Strategic Expansion: GSK's $1.15B acquisition of IDRx bolsters its gastrointestinal (GI) cancer therapy portfolio, marking a significant expansion into the oncology market. Financial Details: The...
Strategic Alignment: The acquisition aligns Intra-Cellular's neuroscience pipeline with J&J's pharmaceutical offerings, positioning J&J for growth in the $48B neuroscience market. Market Potential:...
